secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0001683168-24-003796
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte invests $7M in MyMD for convertible preferred stock and warrants
---------------------------------------------------------------------------

- Invests $7M for Series G Convertible Preferred Stock convertible into 3,854,626 MyMD common shares at $1.816 per share.
- Also receives warrants to purchase up to 3,854,626 MyMD common shares (5-year and 18-month terms) at $1.816 per share.
- Gets right to nominate one board member while owning >20% of MyMD common stock on as-converted basis.
- MyMD filed Certificate of Designations for Series G Preferred with 10% annual dividend, compounded monthly.
- MyMD is a clinical-stage biopharma with Phase 2 data in sarcopenia (MYMD-1) and advancing toward FDA discussions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316824003796/0001683168-24-003796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316824003796/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-003796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer